ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstronauTx, a London-based biotechnology company that aims to develop small-molecule drugs for neurodegenerative diseases, has closed a $61 million series A financing round led by the Novartis Venture Fund. AstronauTx focuses on restoring the function of brain cells called astrocytes. These are more numerous than neurons and play important roles in brain immunity and inflammation. The company is planning a clinical trial of its lead drug candidate, which it has not disclosed, in people with Alzheimer’s disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X